AroCell: resuming coverage following completion of rights issue
Research Note
2019-12-10
16:23
We resume coverage following completion of the rights issue where Redeye acted as financial advisor. Factoring in the transaction and the new number of outstanding shares, we also present a new fair value range.
OB
Oscar Bergman
Disclosures and disclaimers